Q & M Dental Group Ltd - Testing services drove all the growth

19 Nov 2021
  • 3Q21 PATMI rose 69% YoY to S$9.5mn. Earnings modestly exceeded our expectations, at 78% of our adjusted FY21e forecast.
  • All the growth was from COVID-19 PCR test. Dental PATMI is estimated to have declined around 18% YoY in 3Q21. Q & M is on track for a record 17 new clinics in Singapore this year.
  • We are raising our FY21e PATMI by 8% due to higher PCR test earnings. Our BUY recommendation is maintained. The target price is maintained at S$0.82 (post bonus issue). The core dental operations are valued at 25x PE, in line with industry peers. The PCR test business is valued at recently transacted S$60mn. Listed associate, Aoxin Q & M Dental (S$0.27, Not Rated), is valued at market price with a 20% discount.

The Positives

+ COVID-19 PCR test drove earnings growth. Net profit from PCR tests expanded 47% QoQ to S$4.4mn. It accounted for all the earnings growth this quarter. The surge in COVID-19 cases has resulted in a spike in test requirements. We model around S$11mn net earnings from PCR tests in FY21e. We are expecting slower PCR testing revenue as the authorities transit to antigen rapid test (ART) as the default mode of testing.

 

+ Record expansion in clinics. 3Q21 Q & M added 3 new clinics in Singapore. There are plans for another 9 to 10 clinics in 4Q21. The 17 new clinics in 2021 would represent a record expansion for the company.  In 2019, Q & M added 7 new clinics but the pandemic stalled expansion plans in 2020.

 

+ Another quarterly dividend. Q & M announced another quarterly dividend of 1 cent during the quarter. This is the 3rd consecutive quarterly dividend of 1 cent. No guidance or dividend policy was mentioned. The dividend yield for FY21e is around 6%.

 

The Negative

– Dental earnings declined. Earnings from the core dental business were surprisingly weak. Q & M dental revenue only rose 5% YoY. We believe the lockdown in Malaysia and surge in pandemic cases in Singapore may have stifled visitations for the company.

 

Outlook

The record new clinics in FY21 would be a major revenue growth driver in FY22e. Q &M has added much more resources in the recruitment, training and setting of new clinics. The objective is to annually expand 20 new clinics in Singapore per year.

 

Whilst we raise PCR earnings in FY21e, FY22e estimates are unchanged. Authorities are transitioning more towards ART as the main mode for testing PCR patients. PCR will still be an important testing tool for travel and confirmation of COVID-19 patients for hospitalization. Unclear if  Acumen will be developing or commercialising ART test kits.

 

Maintain BUY with unchanged TP of S$0.82 (post bonus issue)

We keep FY21e earnings unchanged. Dental valuation is pegged at 25x PE FY22e, in line with industry peers. Acumen Diagnostics PCR test is valued at S$60mn. This is the implied valuation following the disposal of a 49% stake to associate Aoxin. Our valuation for Acumen Diagnostics is now based on the implied S$60mn valuation. Aoxin’s valuation is marked to market with a 20% discount.

About the author

Paul Chew
Head of Research
Phillip Securities Research Pte Ltd

Paul has 20 years of experience as a fund manager and sell-side analyst. During his time as fund manager, he has managed multiple funds and mandates including capital guaranteed, dividend income, renewable energy, single country and regionally focused funds.

He graduated from Monash University and had completed both his Chartered Financial Analyst and Australian CPA programme.

Latest Reports

Contact us to Open an Account

Need Assistance? Share your Details and we’ll get back to you

IMPORTANT INFORMATION

This material is provided by Phillip Capital Management (S) Ltd (“PCM”) for general information only and does not constitute a recommendation, an offer to sell, or a solicitation of any offer to invest in any of the exchange-traded fund (“ETF”) or the unit trust (“Products”) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. You should read the Prospectus and the accompanying Product Highlights Sheet (“PHS”) for key features, key risks and other important information of the Products and obtain advice from a financial adviser (“FA“) pursuant to a separate engagement before making a commitment to invest in the Products. In the event that you choose not to obtain advice from a FA, you should assess whether the Products are suitable for you before proceeding to invest. A copy of the Prospectus and PHS are available from PCM, any of its Participating Dealers (“PDs“) for the ETF, or any of its authorised distributors for the unit trust managed by PCM.  

An ETF is not like a typical unit trust as the units of the ETF (the “Units“) are to be listed and traded like any share on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Listing on the SGX-ST does not guarantee a liquid market for the Units which may be traded at prices above or below its NAV or may be suspended or delisted. Investors may buy or sell the Units on SGX-ST when it is listed. Investors cannot create or redeem Units directly with PCM and have no rights to request PCM to redeem or purchase their Units. Creation and redemption of Units are through PDs if investors are clients of the PDs, who have no obligation to agree to create or redeem Units on behalf of any investor and may impose terms and conditions in connection with such creation or redemption orders. Please refer to the Prospectus of the ETF for more details.  

Investments are subject to investment risks including the possible loss of the principal amount invested. The purchase of a unit in a fund is not the same as placing your money on deposit with a bank or deposit-taking company. There is no guarantee as to the amount of capital invested or return received. The value of the units and the income accruing to the units may fall or rise. Past performance is not necessarily indicative of the future or likely performance of the Products. There can be no assurance that investment objectives will be achieved.  

Where applicable, fund(s) may invest in financial derivatives and/or participate in securities lending and repurchase transactions for the purpose of hedging and/or efficient portfolio management, subject to the relevant regulatory requirements. PCM reserves the discretion to determine if currency exposure should be hedged actively, passively or not at all, in the best interest of the Products.  

The regular dividend distributions, out of either income and/or capital, are not guaranteed and subject to PCM’s discretion. Past payout yields and payments do not represent future payout yields and payments. Such dividend distributions will reduce the available capital for reinvestment and may result in an immediate decrease in the net asset value (“NAV”) of the Products. Please refer to <www.phillipfunds.com> for more information in relation to the dividend distributions.  

The information provided herein may be obtained or compiled from public and/or third party sources that PCM has no reason to believe are unreliable. Any opinion or view herein is an expression of belief of the individual author or the indicated source (as applicable) only. PCM makes no representation or warranty that such information is accurate, complete, verified or should be relied upon as such. The information does not constitute, and should not be used as a substitute for tax, legal or investment advice.  

The information herein are not for any person in any jurisdiction or country where such distribution or availability for use would contravene any applicable law or regulation or would subject PCM to any registration or licensing requirement in such jurisdiction or country. The Products is not offered to U.S. Persons. PhillipCapital Group of Companies, including PCM, their affiliates and/or their officers, directors and/or employees may own or have positions in the Products. Any member of the PhillipCapital Group of Companies may have acted upon or used the information, analyses and opinions herein before they have been published. 

This advertisement has not been reviewed by the Monetary Authority of Singapore.  

 

Phillip Capital Management (S) Ltd (Co. Reg. No. 199905233W)  
250 North Bridge Road #06-00, Raffles City Tower ,Singapore 179101 
Tel: (65) 6230 8133 Fax: (65) 65383066 www.phillipfunds.com